No Data
No Data
Alto Neuroscience Rises 25.0%
Alto Neuroscience to Participate in Upcoming Investor Conferences
One Mind Accelerator Announces Third Cohort of Mental Health Startups
USPTO Grants Alto Neuroscience Patent for MDD Treatment Covering ALTO-300
Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients With Major Depressive Disorder Characterized by an Electroencephalogram Biomarker
Express News | Alto Neuroscience Announces U.S. Patent Granted Covering Alto-300 as a Treatment for Patients With Major Depressive Disorder Characterized by an Electroencephalogram Biomarker